Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Pharvaris ( (PHVS) ) has provided an announcement.
On July 22, 2025, Pharvaris N.V. entered into an underwriting agreement with Morgan Stanley & Co. LLC and Leerink Partners LLC to issue and sell 9,562,500 ordinary shares and pre-funded warrants to purchase up to 500,000 ordinary shares. The offering, which closed on July 24, 2025, raised approximately $201 million in net proceeds. Pharvaris intends to use these funds to support research and development, hire a sales and marketing team in the U.S., and cover general corporate expenses. This move is expected to enhance Pharvaris’ market position by advancing its clinical programs and expanding its commercial capabilities.
The most recent analyst rating on (PHVS) stock is a Buy with a $31.00 price target. To see the full list of analyst forecasts on Pharvaris stock, see the PHVS Stock Forecast page.
Spark’s Take on PHVS Stock
According to Spark, TipRanks’ AI Analyst, PHVS is a Neutral.
Pharvaris exhibits significant financial difficulties, with no revenue and ongoing losses, resulting in a low financial performance score. Despite some technical momentum, the valuation is poor due to negative earnings. The stock’s overall score is affected by these financial and valuation challenges, despite its technical strength.
To see Spark’s full report on PHVS stock, click here.
More about Pharvaris
Pharvaris N.V. operates in the pharmaceutical industry, focusing on developing oral therapies for hereditary angioedema (HAE). The company is based in the Netherlands and is engaged in late-stage clinical programs aimed at addressing unmet medical needs in HAE treatment.
Average Trading Volume: 105,830
Technical Sentiment Signal: Buy
Current Market Cap: $1.14B
For detailed information about PHVS stock, go to TipRanks’ Stock Analysis page.